Using conventional and molecular epidemiological analyses to target tuberculosis control interventions in a low incidence area.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Using conventional and molecular epidemiological analyses to target tuberculosis control interventions in a low incidence area.

Novartis Found Symp. 1998;217:42-54; discussion 54-6. Unique Identifier : AIDSLINE MED/99134959
Hopewell PC; Division of Pulmonary and Critical Care Medicine, San Francisco; General Hospital, CA 94110, USA.

Abstract: To consolidate the gains made in controlling tuberculosis in industrialized countries in the past five years, we must analyse carefully the epidemiology of the disease and the effectiveness of various control interventions. In San Francisco we have performed conventional and molecular epidemiological analyses that have shown that there are in essence two parallel epidemiological patterns, one in the foreign-born population and the second among US-born persons, with little interaction between them. Most tuberculosis in the foreign-born population is a result of endogenous reactivation of latent infection, whereas recent infection with rapid progression to illness is a more frequent course in US-born cases. Among the US-born cases specific risk factors--homelessness, HIV infection, drug abuse--are highly prevalent. Although there has been a progressive reduction in the number of cases and in the proportion resulting from recent infection in San Francisco in the past five years, there continues to be a high proportion of cases that result from recent infection among US-born persons. These findings suggest that existing control interventions should be tailored to specific target groups and that new interventions are needed to provide for increased efficacy.

Keywords: JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL Epidemiology, Molecular Homeless Persons Human Incidence Risk Factors San Francisco/EPIDEMIOLOGY Support, U.S. Gov't, P.H.S. Tuberculosis, Pulmonary/*EPIDEMIOLOGY/*GENETICS/MORTALITY/ PREVENTION & CONTROL
990530
A9950903

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .